Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 20

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 870 Additional paid-in capital190,499,662 169,705,480 Accumulated other comprehensive loss(395,966)(428,809)Accumulated deficit(187,247,186)(175,289,630)Total stockholders' equity (deficit)2,857,903 (6,012,089)Total liabilities and stockholders' equity (deficit)$30,748,574 $22,101,131 

See accompanying notes.

1

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

Three months ended September 30,Nine months ended September 30,2025202420252024RevenueRoyalty revenue$2,262 $41,691 $6,517 $73,431 Total revenue2,262 41,691 6,517 73,431 Operating expensesGeneral and administrative2,499,242 2,041,268 7,186,272 7,159,979 Research and development1,175,168 2,681,772 4,901,311 10,969,066 Royalty expense— — — 7,674 Total operating expenses3,674,410 4,723,040 12,087,583 18,136,719 Loss from operations(3,672,148)(4,681,349)(12,081,066)(18,063,288)Other income (expense)Sale of royalty and milestone rights, net— — — 20,379,376 Other income (expense), net109,382 (21,152)123,510 (863,289)Net income (loss)$(3,562,766)$(4,702,501)$(11,957,556)$1,452,799 Foreign currency translation adjustments6,860 22,935 32,843 (1,729)Comprehensive income (loss)$(3,555,906)$(4,679,566)$(11,924,713)$1,451,070 Income (loss) per common share:Basic$(0.28)$(0.55)$(1.18)$0.17 Diluted$(0.28)$(0.55)$(1.18)$0.17 Weighted average number of shares